These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27247567)

  • 41. Clinical characterization and mutation spectrum in Caribbean Hispanic families with Lynch syndrome.
    Cruz-Correa M; Diaz-Algorri Y; Pérez-Mayoral J; Suleiman-Suleiman W; Gonzalez-Pons Mdel M; Bertrán C; Casellas N; Rodríguez N; Pardo S; Rivera K; Mosquera R; Rodriguez-Quilichini S
    Fam Cancer; 2015 Sep; 14(3):415-25. PubMed ID: 25782445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer.
    Truninger K; Menigatti M; Luz J; Russell A; Haider R; Gebbers JO; Bannwart F; Yurtsever H; Neuweiler J; Riehle HM; Cattaruzza MS; Heinimann K; Schär P; Jiricny J; Marra G
    Gastroenterology; 2005 May; 128(5):1160-71. PubMed ID: 15887099
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PMS2 involvement in patients suspected of Lynch syndrome.
    Niessen RC; Kleibeuker JH; Westers H; Jager PO; Rozeveld D; Bos KK; Boersma-van Ek W; Hollema H; Sijmons RH; Hofstra RM
    Genes Chromosomes Cancer; 2009 Apr; 48(4):322-9. PubMed ID: 19132747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nine novel pathogenic germline mutations in MLH1, MSH2, MSH6 and PMS2 in families with Lynch syndrome.
    Rahner N; Friedrichs N; Wehner M; Steinke V; Aretz S; Friedl W; Buettner R; Mangold E; Propping P; Walldorf C
    Acta Oncol; 2007; 46(6):763-9. PubMed ID: 17653898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
    Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
    Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Constitutional mismatch repair deficiency and Lynch syndrome among consecutive Arab Bedouins with colorectal cancer in Israel.
    Abu Freha N; Leibovici Weissman Y; Fich A; Barnes Kedar I; Halpern M; Sztarkier I; Behar DM; Arbib Sneh O; Vilkin A; Baris HN; Gingold R; Lejbkowicz F; Niv Y; Goldberg Y; Levi Z
    Fam Cancer; 2018 Jan; 17(1):79-86. PubMed ID: 28608265
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of DNA Mismatch Repair Protein Abnormalities in Sudanese Colorectal Cancer Patients Using Immunohistochemical Methods.
    Zakout YM; Lanza G
    J Gastrointest Cancer; 2019 Sep; 50(3):530-536. PubMed ID: 29850986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing how reduced expression levels of the mismatch repair genes MLH1, MSH2, and MSH6 affect repair efficiency.
    Kansikas M; Kasela M; Kantelinen J; Nyström M
    Hum Mutat; 2014 Sep; 35(9):1123-7. PubMed ID: 24924810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC).
    van der Klift H; Wijnen J; Wagner A; Verkuilen P; Tops C; Otway R; Kohonen-Corish M; Vasen H; Oliani C; Barana D; Moller P; Delozier-Blanchet C; Hutter P; Foulkes W; Lynch H; Burn J; Möslein G; Fodde R
    Genes Chromosomes Cancer; 2005 Oct; 44(2):123-38. PubMed ID: 15942939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation.
    McCarthy AJ; Capo-Chichi JM; Spence T; Grenier S; Stockley T; Kamel-Reid S; Serra S; Sabatini P; Chetty R
    J Pathol Clin Res; 2019 Apr; 5(2):115-129. PubMed ID: 30387329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.
    Zeinalian M; Emami MH; Salehi R; Naimi A; Kazemi M; Hashemzadeh-Chaleshtori M
    J Gastrointest Cancer; 2015 Jun; 46(2):118-25. PubMed ID: 25722176
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence of germline variants in Lynch syndrome-related genes among Japanese endometrial cancer patients aged 40 years or younger.
    Makabe T; Yamagami W; Hirasawa A; Miyabe I; Wakatsuki T; Kikuchi M; Takahashi A; Noda J; Yamamoto G; Aoki D; Akagi K
    Int J Clin Oncol; 2021 Sep; 26(9):1767-1774. PubMed ID: 34115236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review.
    Yokoyama T; Takehara K; Sugimoto N; Kaneko K; Fujimoto E; Okazawa-Sakai M; Okame S; Shiroyama Y; Yokoyama T; Teramoto N; Ohsumi S; Saito S; Imai K; Sugano K
    BMC Cancer; 2018 May; 18(1):576. PubMed ID: 29783979
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Success of referral to genetic counseling after positive lynch syndrome screening test.
    Irons RF; Contino KM; Horte JJ; Levin B; Mattie KD; Wight M; Kwiatt ME; Behling KC; Edmonston TB; McClane SJ
    Int J Colorectal Dis; 2017 Sep; 32(9):1345-1348. PubMed ID: 28664346
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of colonic and endometrial carcinomas in Portuguese families with hereditary nonpolyposis colorectal carcinoma significantly increases the probability of detecting a pathogenic mutation in mismatch repair genes, primarily the MSH2 gene.
    Lage PA; Albuquerque C; Sousa RG; Cravo ML; Salazar M; Francisco I; Maia L; Claro I; Suspiro A; Rodrigues P; Raposo H; Fidalgo PA; Nobre-Leitão C
    Cancer; 2004 Jul; 101(1):172-7. PubMed ID: 15222003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel variants of unknown significance in the
    Liccardo R; Della Ragione C; Mitilini N; De Rosa M; Izzo P; Duraturo F
    Cancer Manag Res; 2019; 11():6719-6725. PubMed ID: 31410062
    [No Abstract]   [Full Text] [Related]  

  • 60. Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management.
    Ramsoekh D; Wagner A; van Leerdam ME; Dooijes D; Tops CM; Steyerberg EW; Kuipers EJ
    Hered Cancer Clin Pract; 2009 Dec; 7(1):17. PubMed ID: 20028567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.